Vir Biotechnology Prospective Treatment for Hepatitis Delta Gets EU Advisory Committee Recommendation

MT Newswires Live11-19

Vir Biotechnology (VIR) late Monday said European regulators are expected to approve its product candidates to treat a relatively rare form of hepatitis and liver disease as an orphan drug.

A European Medicines Agency advisory panel recommended approving tobevibart and elebsiran as an orphan drug for the treatment of chronic hepatitis delta. The recommendation follows encouraging preliminary data from a phase 2 trial evaluating the efficacy of the drug combination in adults with hepatitis delta infections.

The US Food and Drug Administration in June issued a fast-track designation for the tobevibart and elebsirann, which will expedite the review process.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment